

# α,γ-Diamino Acids: Asymmetric Synthesis of New Constrained 6-Amino-3-azabicyclo[3.2.1]octane-6-carboxylic Acids

Francesco Caputo, Cristian Cattaneo, Francesca Clerici, Maria Luisa Gelmi,\* and Sara Pellegrino

Istituto di Chimica Organica "A. Marchesini", Facoltà di Farmacia, Università di Milano, Via Venezian 21, I-20133 Milano, Italy

marialuisa.gelmi@unimi.it

Received July 5, 2006



The synthesis of two new diastereometric 6-amino-3-azabicyclo[3.2.1]octane-6-carboxylic acids *exo*- and *endo*-**8**,**9** is reported using *exo*- and *endo*-norbornene amino acids as chiral building blocks. This method provides a fast access to optically pure amino acids **8** and **9** which can be considered both  $\alpha$ , $\gamma$ - and  $\alpha$ , $\delta$ -diamino acids containing sterical constraints and characterized by  $\alpha$ , $\alpha$ -disubstitution.

### Introduction

The syntheses and the biological activities of molecules containing the 3-azabicyclo[3.2.1]octane scaffold are documented by more than 250 patents which indicates that this ring could be the pharmacophore of a bioactive molecule or a substituent of a different bioactive scaffold. Depending on the substitution pattern of the 3-azabicyclo[3.2.1]octane ring, different activities were reported, and many of these compounds were used for treating central nervous system disorders. Among these molecules, the amino-substituted compounds are of relevance,<sup>1</sup> as well as the carboxylic acid derivatives.<sup>2</sup>

The diastereo- and enantioselective preparation of new constrained amino acids has been one of our synthetic targets since the 1999s.<sup>3</sup> Conformationally restricted amino acids are of great interest and have assumed a prominent role in drug design and development.<sup>4</sup> Going on our research program and considering the general biological importance of 3-azabicyclo-[3.2.1]octane derivatives and in view of their use in peptidomimetic synthesis, we planned the preparation of compounds *exo-* and *endo-***8**,**9** (Scheme 1) functionalized both with amino and carboxy groups on C-6 which, to our knowledge, are unknown compounds. 6-Amino-3-azabicyclo[3.2.1]octane-6-carboxylic acids can be considered both  $\alpha$ , $\gamma$ - and  $\alpha$ , $\delta$ -diamino acids containing sterical constraints and characterized by  $\alpha$ , $\alpha$ -disubstitution. Their features, such as the  $\alpha$ , $\alpha$ -disubstitution, which gives metabolic stability, the conformational rigidity, and the presence of two amino groups and one carboxy group, make them very interesting substrates to be used in peptidomimetic syntheses. Constrained amino acids are able to modulate the conformation and, as a consequence, the properties of peptides and their biological activity.<sup>4c,5</sup> In particular, few examples of  $\delta$ -amino acids are reported even if they seem to be very promising in view of the synthesis of peptidomimetics.<sup>5a,b</sup>

To ensure the preparation of both diastereomers of the title compounds 8 and 9, in enantiopure form too, our retrosynthetic

<sup>\*</sup> To whom correspondence should be addressed. Phone: +390250314481. Fax: +390250314476.

<sup>(1) (</sup>a) Heng, R.; Revesz, L.; Schlapbach, A.; Waelchli, R. PCT Int. Appl. 2005, PIXXD2 WO 2005103054 A2 20051103; Chem. Abstr. 2005, 143, 440438. (b) Hamamoto, I.; Takahashi, J.; Yano, M.; Hanai, D.; Iwasa, T. PCT Int. Appl. 2005, PIXXD2 WO 2005095380 A1 20051013; *Chem. Abstr.* 2005, 143, 386926. (c) Evertsson, E.; Inghardt, T.; Lindberg, J.; Linusson, A.; Giordanetto, F. PCT Int. Appl. 2005, PIXXD2 WO 2005066132 A1 20050721; Chem. Abstr. 2005, 143, 172772. (d) Breining, S. R.; Bhatti, B. S.; Hawkins, G. D.; Miao, L.; Anatoly, P.; Teresa, Y.; Miller, C. H. PCT Int. Appl. 2005, PIXXD2 WO 2005037832 A2 20050428; Chem. Abstr. **2005**, *142*, 430157. (e) Dong, J.; Han, H.; Geng, B.; Li, X.; Gong, Z.; Liu, K. J. Peptide Res. **2005**, *65*, 440–444. (f) Coe, J. W.; Iredale, P. A.; McHardy, S. F.; McLean, S. U.S. Patent Appl. Publ. 2005, USXXCO US 2005043345 A1; *Chem. Abstr.* **2005**, *142*, 233377. (g) Bridger, G.; McEachern, E. J.; Skerlj, R.; Schols, D. U.S. Patent Appl. Publ. 2004, USXXCO US 2004209921 A1 20041021; Chem. Abstr. 2004, 141, 379809. (h) Lew, W.; Wu, H.; Chen, X.; Graves, B. J.; Escarpe, P. A.; MacArthur, H. L.; Mendel, D. B.; Kim, C. U. Bioorg. Med. Chem. Lett. 2000, 10, 1257 1260. (i) Yamashita, A.; Takahashi, N.; Mochizuki, D.; Tsujita, R.; Yamada, S.; Kawakubo, H.; Suzuki, Y.; Watanabe, H. Bioorg. Med. Chem. Lett. 1997, 7, 2303-2306. (j) Takahashi, N.; Mochizuki, D. U.S. Patent Appl. USXXAM US 5658923A 19970819, 1997; Chem. Abstr. 1997, 127, 248269. (k) Rico, B.; Galvez, E.; Izquierdo, M. L.; Arias, M. S.; Orjales, A.; Berisa, A.; Labeaga, L. J. Heterocycl. Chem. 1994, 31, 313-318. (1) Keasling, H. H.; Moffett, R. B. J. Med. Chem. 1971, 14, 1106-1112.



plan features the norbornene amino acids **1** as suitable starting materials (Scheme 1).

Compounds **1** are readily prepared as endo/exo diastereomers, both in racemic<sup>6</sup> and in enantiopure form,<sup>3b</sup> by using the Diels–

(3) (a) Caputo, F.; Clerici, F.; Gelmi, M. L.; Nava, D.; Pellegrino, S. *Tetrahedron* **2006**, *62*, 1288–1294 and references therein. (b) Caputo, F.; Clerici, F.; Gelmi, M. L.; Pellegrino, S.; Pocar, D. *Tetrahedron: Asymmetry* **2006**, *17*, 1430–1436.

(4) (a) Gelmi, M. L.; Pocar, D. Org. Prep. Proc. Int. 2003, 35, 141–205. (b) Cativiela, C.; Diaz-de-Villegas, M. D. Tetrahedron: Asymmetry 2000, 11, 645–732. (c) Advances in Amino Acids Mimetics and Peptidomimetics; Abell, A., Ed.; JAI Press Inc.: London, UK, 1998.

(5) (a) Trabocchi, A.; Guarna, F.; Guarna, A. *Curr. Org. Chem.* 2005, 9, 1127–1153. (b) Baldauf, C.; Gunther, R.; Hofmann, H.-G. J. Org. Chem. 2004, 69, 6214–6220. (c) Kimmerlin, T.; Seebach, D. J. Peptide Res. 2005, 65, 229–260. (d) Ispida, H.; Kyakuno, M.; Oishi, S. *Biopolymers* 2004, 76, 669–82. (e) Lelais, G.; Seebach, D. *Biopolymers* 2004, 76, 206–243. (f) Souers, A. J.; Ellman, J. A. *Tetrahedron* 2001, 57, 7431–7448. (g) *Peptidomimetic Protocols (methods in Molecular Medicine)*; Kazmierski, W. M., Ed.; Humana Press Inc.: Totowa, NJ, 1999. (h) Hanessian, S.; McNaughton-Smith, G.; Lombart, H.; Lubell, W. D. *Tetrahedron* 1997, 53, 12789–12854. (i) Hruby, W.; Li G., Haskell-Luevano, C.; Shenderovic, M. *Biopolymers* 1997, *43*, 219–248. (j) Humphrey, J. M.; Chamberlin, A. R. *Chem. Rev.* 1997, *97*, 2243–2266.

(6) Bueno, M. P.; Cativiela, C.; Finol, C.; Mayoral, J. A. *Can. J. Chem.* **1987**, *65*, 2182–2186.

(7) Iriepa, I.; Madrid, A. I.; Morreale, A.; Gálvez, E.; Bellanato, J. J. Mol. Struct. 2003, 651–653, 585–591 and references therein.

(8) Kim, D.-I.; Schweri, M. M.; Deutsch, H. M. J. Med. Chem. 2003, 46, 1456-1464.





 $^a$  Reagents and conditions: (i) OsO4, NMO, acetone/H2O, 25 °C; (ii) NaIO4, dioxane/H2O, 25 °C.

Alder reaction starting from 2-aminoacrylate derivatives and cyclopentadiene. The disconnection of ring B of norbornenes 1 by an oxidative reaction ( $C_5-C_6$  cleavage) yields the cyclopentyl derivatives 3/4 (ring A in both compounds 1 and 3/4) substituted with the amino acid function and with two formyl groups with the proper regiochemistry and *cis* configuration. From these key intermediates, the formation of ring C of the 3-azabicyclo[3.2.1]-octane skeleton was assured by a reductive amination reaction. By using a very efficient protocol, starting from a mixture of protected norbornene amino acids *exo*-1 and *endo*-1, the new diastereomeric 6-amino-3-azabicyclo[3.2.1]octane-6-carboxylic acids *exo*-8,9 and *endo*-8,9 were prepared in good yields. Amino acids 8 and 9 are orthogonally protected, allowing the selective deprotection of both the acid and the two different amino groups.

# Results

The key starting reagents for the preparation of the amino acids containing the 3-azabicyclo[3.2.1]octane skeleton were the norbornene derivatives exo-1a and endo-1a as well as the corresponding enantiopure compounds exo-1b and endo-1b. The C<sub>4</sub>-C<sub>5</sub> double bond of the norbornene ring was cleaved by a two-step oxidative process. First, racemic compounds exo-1a and endo-1a were transformed into the corresponding dihydroxy derivatives 2 by allowing 1 to react with N-methylmorpholine-*N*-oxide (NMO) in acetone/ $H_2O$ , in the presence of a catalytic amount of osmium tetroxide (Scheme 2). The diol derivatives exo-2a (86%) and endo-2a (84%) were obtained in pure form as single diastereomers characterized by the *cis* relationship between both the hydroxy groups and the bridge, as demonstrated by a NOESY experiment on exo-2a. In fact, spatial proximity between endo H-3 ( $\delta$  1.34) and H-5 ( $\delta$  3.73) and between H-6 ( $\delta$  3.97) and the methyl group of the acetyl group  $(\delta 1.94)$  was observed.

The cyclopentyl derivatives functionalized with two formyl groups with the proper stereochemistry were obtained by

<sup>(2) (</sup>a) Butora, G.; Goble, S. D.; Pasternak, A.; Yang, L.; Zhou, C.; Moyes, C. R. PCT Int. Appl. 2004, PIXXD2 WO 2004094371 A2 20041104; *Chem. Abstr.* **2004**, *141*, 410822. (b) Chandrakumar, N. S.; Chen, B. B.; Clare, M.; Desai, B. N.; Djuric, S. W.; Docter, S. H.; Gasiecki, A. F.; Haack, R. A.; Liang, C.-D. PCT Int. Appl. 1996, PIXXD2 WO 9611192 A1 19960418; *Chem. Abstr.* **1996**, *125*, 142545. (c) Buckley, B. R.; Page, P. C. B.; Heaney, H.; Sampler, E. P.; Carley, S.; Brocke, C.; Brimble, M. A. *Tetrahedron* **2005**, *61*, 5876–5888. (d) Brocke, C.; Brimble, M. A.; Lin, D. S.-H.; McLeod, M. D. *Synlett* **2004**, *13*, 2359–2363. (e) House, H. O.; Mueller, H. C. *J. Org. Chem.* **1962**, *27*, 4436–4439. (f) Lowe, J. A., III; Drozda, S. E.; McLean, S.; Bryce, D. K.; Crawford, R. T.; Snider, R. M.; Longo, K. P.; Nagahisa, A.; Tsuchiya, M. *J. Med. Chem.* **1994**, *37*, 2831–2840. (g) King, F. D. PCT Int. Appl. 1992, PIXXD2 WO 9212149 A1 19920723; *Chem. Abstr.* **1992**, *117*, 212337.



<sup>a</sup> Reagents and conditions: (i) p-methoxybenzylamine, NaBH(OAc)<sub>3</sub>, AcOH (cat.), ClCH2CH2Cl, 25 °C.

cleaving the  $C_4$ - $C_5$  bond of compounds 2 with sodium periodate as the oxidant in dioxane/H<sub>2</sub>O (8:1) at room temperature (4 h). Bisaldehydes 3a and 4a were quantitatively obtained from exo-2a and endo-2a, respectively (Scheme 2).

Their structure was confirmed by <sup>1</sup>H NMR, which showed the presence of two singlets in the  $\delta$  9.7–9.8 region.

The bisaldehydes are not very stable, and it was chosen to transform the crude reaction mixtures directly into the corresponding 3-azabicyclo[3.2.1]octane derivatives. A reductive amination was performed using *p*-methoxybenzylamine, as the nitrogen donor, and sodium triacetoxyborohydride, as reducing agent (1.3 equiv). The reaction was performed at room temperature (4 h) in 1,2-dichloroethane and in the presence of a catalytic amount of acetic acid. Methyl 6-acetamido-3-azabicyclo-[3.2.1]octane-6-carboxylate derivative exo-5a (61%) was obtained from 3a. Compound endo-5a was isolated in 53% yield starting from 4a (Scheme 3).

This synthetic protocol suffers from some limitations related to (i) the efficiency of the exo/endo norbornenes 1 separation,



#### SCHEME 4. Orthogonal Deprotection<sup>a</sup>

and (ii) the necessity to perform the reaction twice, both starting from the exo and the endo norbornenes. A more efficient synthetic protocol was developed consisting of the preparation of the exo/endo mixture of compounds 5a by using the same synthetic procedure described for pure diastereomers and in their easy separation by column chromatography in the final step. The mixture of exo- and endo-1a (7:3) was transformed into a mixture of exo/endo-3-azabicyclo[3.2.1]octane amino acid derivatives exo-5a (41%) and endo-5a (15%), through the diol derivatives 2a and bisaldehydes 3a/4a.

The enantiopure amino acids (-)-exo-5b (57%) and (-)-endo-5b (58%) (Scheme 3) were prepared following the same synthetic scheme starting from enantiopure compounds (-)-exo-1b and (+)-endo-1b, transformed into the diol derivatives (-)-exo-2b and (+)-endo-2b, oxidized to bisaldehyde 3b and 4b, respectively (Scheme 2).

Compounds 5 are orthogonally protected diamino acids which are selectively deprotected to each functional group. Compound exo-5a was selected to study the orthogonal deprotection. The 3-aza group was first deprotected, aiming to prepare the NH azabicyclo[3.2.1]octane derivatives which are valuable and alternative starting materials for the preparation of other 3-Nsubstituted amino acids. To remove the N-p-methoxybenzyl group (PMB), an oxidative process was performed using cerium ammonium nitrate (CAN) in acetone/H2O (9:1) at room temperature. This method is reported in the literature, but its straightforward application in the present case caused difficulties because of the solubility of the amino acid derivative in water. The problem was overcome by treating the reaction mixture with solid NaHCO<sub>3</sub> followed by its chromatography on silica gel. Compound exo-6a was isolated in 90% yield. The same synthetic protocol allowed us to transform endo-5a into amino acid endo-6a (62%). The methyl ester group of exo-5a and endo-5a was selectively hydrolyzed using basic conditions (EtOH/ KOH). The corresponding acids exo-7 (95%) and endo-7 (99%) were isolated, respectively. Both the amino and the carboxy functions were deprotected in acid conditions (6 N HCl at 100 °C, 24 h). Amino acids exo-8,9 and endo-8,9 were obtained in quantitative yield, as bishydrochlorides, from exo-5a,6a and endo-5a,6a, respectively.

<sup>a</sup> Reagents and conditions: (i) CAN, acetone/H<sub>2</sub>O, 25 °C; (ii) KOH, EtOH (95%), 120 °C; (iii) 6 N HCl, 100 °C; (iv) MeOH, Na, 0 °C, then **5b**, 100 °C; (v) SOCl<sub>2</sub>, MeOH, reflux.

CO2R

. CO₂Me

The hydrolysis of ester and amido functions of enantiopure compounds *exo-***5b** and *endo-***5b** was successfully achieved with MeONa in methanol at reflux for 50 h. Acids (-)*-exo-***8** (45%) and (-)*-endo-***8** (60%) were obtained, respectively. Finally, the reaction of amino acid *exo-***8** with SOCl<sub>2</sub> and MeOH gave the corresponding methyl ester *exo-***10** in 89% yield. All compounds were characterized by spectroscopic data, and as examples, the NMR discussion on the conformation of compounds **5** is reported in the Supporting Information (Figure S1).

In conclusion, a very efficient protocol for the preparation of two new diastereomeric constrained diamino acids containing the 3-azabicyclo[3.2.1]octane skeleton was developed. They were prepared in good yields and in enantiopure form starting from readily available enantiopure norbornene amino acids.

Amino acid derivatives **5** are orthogonally protected, and this allowed the selective deprotection of the *N*-3 atom or of the amino group on C-6. In particular, the NH compounds **6** are expected to be valuable starting materials for the selective functionalization of amino acid groups on the N-3 atom. Furthermore, these compounds are very promising amino acids to be used for peptidomimetic synthesis.

## **Experimental Section**

Compounds *exo*-**1a**,<sup>6</sup> *endo*-**1a**,<sup>6</sup> *exo*-**1b**,<sup>3b</sup> and *endo*-**1b**<sup>3b</sup> were prepared according to a known procedure.

General Procedure for the Synthesis of Diols 2. Compound 1 [exo-1a or endo-1a or a mixture of exo-1a/endo-1a (7:3) (209 mg, 1 mmol); exo-1b or endo-1b (409.6 mg, 1 mmol)] was suspended in a mixture of acetone/H2O (6 mL, 10:1). After addition of N-methylmorpholine-N-oxide (176 mg, 1.5 mmol) and OsO<sub>4</sub> (1.35 mg, 0.005 mmol), the solution turned brown. The reaction mixture was stirred at room temperature for 8 h after which the solvent was evaporated. The crude reaction mixture was filtered on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 5:1). Pure compound 2 (*exo*-2a, 209 mg, 86%; endo-2a, 204 mg, 84%; exo-2a/endo-2a, 202 mg, 83%) was obtained after crystallization. The crude reaction mixture containing 2b was taken up with a saturated solution of Na<sub>2</sub>S<sub>2</sub>O<sub>4</sub> (5 mL) and extracted with  $CH_2Cl_2$  (3 × 5 mL). After drying of the organic layer with Na2SO4 and column chromatography on silica gel (CH2- $Cl_2/MeOH = 20:1$ ), pure compound **2b** (*exo*-**2b**, 404 mg, 90%; endo-2b, 430 mg, 97%) was isolated.

Methyl (1*R*\*,2*S*\*,4*S*\*,5*S*\*,6*R*\*)-2-Acetylamino-5,6-dihydroxybicyclo[2.2.1]heptane-2-carboxylate *exo*-2a: Mp 161 °C (MeOH/ *i*Pr<sub>2</sub>O); IR  $\nu_{max}$  3500–3100, 1735, 1651 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 3.97 (d, *J* = 6.2 Hz, 1 H), 3.73 (d, *J* = 5.0 Hz, 1 H), 3.67 (s, 3 H), 2.71 (br s, 1 H), 2.22 (dd, *J* = 13.8, 5.0 Hz, 1 H), 2.09 (br s, 1 H), 1.94 (s, 3 H), 1.94–1.91 (m, 1 H), 1.64 (d, *J* = 10.9 Hz, 1 H), 1.34 (dd, *J* = 13.8, 2.9 Hz, 1 H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 174.6, 172.9, 73.9, 69.3, 62.6, 51.8, 50.4, 43.3, 38.3, 31.3, 21.0; *m/z* 244.2 [M<sup>+</sup>]. Anal. Calcd for C<sub>11</sub>H<sub>17</sub>NO<sub>5</sub>: C, 54.31; H, 7.04; N, 5.76. Found: C, 54.28; H, 7.10; N, 5.68.

Methyl (1*S*\*,2*S*\*,4*R*\*,5*R*\*,6*S*\*)-2-Acetylamino-5,6-dihydroxybicyclo[2.2.1]heptane-2-carboxylate *endo*-2a: Mp 186 °C (MeOH/ *i*Pr<sub>2</sub>O); IR  $\nu_{max}$  3346, 1731, 1694 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 3.74 (dd, *J* = 6.2, 1.4 Hz, 1 H), 3.66 (s, 3 H), 3.57 (dd, *J* = 5.8, 1.4 Hz, 1 H), 2.38 (dd, *J* = 13.9, 2.5 Hz, 1 H), 2.23 (br s, 1 H), 2.16–2.14 (m, 1 H), 1.97 (dt, *J* = 10.6, 1.1 Hz, 1 H), 1.88 (s, 3 H), 1.65 (dt, *J* = 10.6, 1.5 Hz, 1 H), 1.54 (ddd, *J* = 14.0, 5.1, 0.7 Hz, 1 H); <sup>13</sup>C NMR (CD<sub>3</sub>OD) δ 173.1, 171.5, 72.8, 68.9, 63.8, 52.3, 51.6, 43.9, 38.8, 31.8, 20.8; *m*/z 244.2 [M<sup>+</sup>]. Anal. Calcd for C<sub>11</sub>H<sub>17</sub>NO<sub>5</sub>: C, 54.31; H, 7.04; N, 5.76. Found: C, 54.25; H, 7.12; N, 5.67.

(-)-8-Phenylmenthyl (1*R*,2*S*,4*S*,5*S*,6*R*)-2-Acetylamino-5,6dihydroxybicyclo[2.2.1]heptane-2-carboxylate *exo*-2b: Mp 235 °C (CH<sub>2</sub>Cl<sub>2</sub>/*i*-Pr<sub>2</sub>O);  $[\alpha]^{25}_{D} = -9.1^{\circ}$  (*c* 0.5, MeOH); IR  $\nu_{max}$  3360– 3300, 1715, 1647 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD)  $\delta$  7.34–7.11 (m, 5 H), 4.83–4.71 (m, 1 H), 3.97 (d, *J* = 6.2 Hz, 1 H), 3.66 (d, *J* = 5.5 Hz, 1 H), 2.61 (br s, 1 H), 2.26 (dd, J = 13.9, 5.1 Hz, 1 H), 2.05–1.77 (m, 3 H), 1.90 (s, 3 H), 1.55–0.72 (m, 9 H), 1.35 (s, 3 H), 1.24 (s, 3 H), 0.86 (d, J = 6.6 Hz, 3 H); <sup>13</sup>C NMR (CD<sub>3</sub>OD)  $\delta$  172.9, 171.6, 153.3, 128.5, 125.9, 124.9, 77.4, 73.8, 69.3, 62.6, 50.8, 50.2, 43.7, 40.9, 39.7, 38.1, 35.0, 31.5, 29.9, 29.6, 26.8, 24.1, 23.5, 21.9; m/z 466.4 [+Na]. Anal. Calcd for C<sub>26</sub>H<sub>37</sub>NO<sub>5</sub>: C, 70.40; H, 8.41; N, 3.16. Found: C, 70.33; H, 8.45; N, 3.10.

(-)-8-Phenylmenthyl (15,25,4*R*,5*R*,6*S*)-2-Acetylamino-5,6dihydroxybicyclo[2.2.1]heptane-2-carboxylate *endo*-2b: Mp 249 °C;  $[\alpha]^{25}_{D} = +13^{\circ}$  (*c* 0.5, MeOH); IR  $\nu_{max}$  3375, 1704, 1649 cm<sup>-1</sup>; <sup>1</sup> H NMR (CDCl<sub>3</sub>)  $\delta$  7.40–7.16 (m, 5 H), 5.00 (s, 1 H, exch.), 4.69–4.59 (m, 1 H), 3.90 (d, *J* = 5.9 Hz, 1 H), 3.82 (d, *J* = 6.3 Hz, 1 H), 2.22–2.00 (m, 3 H), 2.00–1.80 (m, 4 H), 1.81 (s, 3 H), 1.79–1.42 (m, 4 H), 1.34 (s, 3 H), 1.30–0.80 (m, 2 H), 1.17 (s, 3 H), 0.87 (d, *J* = 6.7 Hz, 3 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  171.8, 169.9, 152.9, 128.4, 125.9, 125.1, 77.7, 73.2, 69.4, 63.7, 52.3, 49.8, 44.4, 41.0, 39.8, 39.2, 35.0, 32.5, 31.6, 28.9, 27.0, 25.1, 23.3, 22.0; *m/z* 466.4 [+Na]. Anal. Calcd for C<sub>26</sub>H<sub>37</sub>NO<sub>5</sub>: C, 70.40; H, 8.41; N, 3.16. Found: C, 70.47; H, 8.39; N, 3.13.

General Procedure for the Preparation of Bisaldehydes 3 and 4. Compound 2 (2a, 243 mg, 1 mmol; 2b, 443 mg, 1 mmol) was dissolved in a mixture of dioxane/H<sub>2</sub>O (5 mL, 8:1). NaIO<sub>4</sub> was added (1.7 g, 7.92 mmol), and the mixture was stirred at room temperature for 2 h. The solvent was evaporated, and the reaction mixture was taken up with CHCl<sub>3</sub> (10 mL), and the salts were filtered and washed with CHCl<sub>3</sub>. The organic solution was collected, and after solvent elimination, the crude aldehydes 3 or 4 [*exo/endo-*2a, 3a,4a (240 mg); *exo-*2a, 3a (232 mg); *endo-*2a, 4a (234 mg); *exo-*2b, 3b (395 mg); *endo-*2b, 4b (398 mg)] were isolated and used without further purification.

**Methyl (1***S*\*,2*R*\*,4*S*\*)-1-Acetylamino-2,4-diformylcyclopentanecarboxylate 3a: crude compound; IR  $\nu_{max}$  3346, 1731, 1694 cm<sup>-1</sup>; <sup>1</sup> H NMR (CDCl<sub>3</sub>)  $\delta$  9.76 (s, 1 H), 9.71 (s, 1 H), 6.50 (s, 1 H, exch.), 3.77 (s, 3 H), 3.25–3.05 (m, 1 H), 2.50 (dd, *J* = 13.9, 3.7 Hz, 1 H), 2.40–1.90 (m, 4 H), 1.91 (s, 3 H); <sup>13</sup>C NMR  $\delta$  202.7, 172.0, 170.8, 66.6, 57.2, 53.3, 47.4, 37.0, 24.7, 22.9; *m/z* 242.1 [M<sup>+</sup>].

Methyl (1*S*\*,2*S*\*,4*R*\*)-1-Acetylamino-2,4-diformylcyclopentanecarboxylate 4a: crude compound; IR  $\nu_{max}$  3391, 1728, 1658 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 9.68 (s, 1 H), 9.67 (s, 1 H), 6.70 (s, H, exch.), 3.69 (s, 3 H), 3.20–2.90 (m, 1 H), 2.60–1.90 (m, 4 H), 2.01 (s, 3 H); <sup>13</sup>C NMR δ 201.7, 200.0, 173.0, 170.5, 65.7, 58.4, 53.2, 48.9, 36.8, 27.2, 23.9; *m/z* 242.1 [M<sup>+</sup>].

(-)-8-Phenylmenthyl (1*S*,2*R*,4*S*)-1-Acetylamino-2,4-diformylcyclopentanecarboxylate 3b: crude compound; IR  $\nu_{max}$  3428, 1759, 1633 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  9.73 (s, 1 H), 9.48 (d, *J* = 0.81 Hz, H), 7.39–7.11 (m, 5 H), 6.35 (s, 1 H, exch.), 4.93–4.88 (m, 1 H), 3.02–2.92 (m, 1 H), 2.40–2.31 (m, 1 H), 2.25 (dd, *J* = 14.0, 2.3 Hz, 1 H), 2.20–2.13 (m, 1 H), 2.12–1.75 (m, 5 H), 1.84 (s, 3 H), 1.68 (dd, *J* = 14.0, 10.1 Hz, 1 H), 1.60–1.50 (m, 1 H), 1.32 (s, 3 H), 1.28–1.18 (m, 1 H), 1.14 (s, 3 H), 1.10–0.97 (m, 2 H), 0.93 (d, *J* = 6.6 Hz, 3 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  202.2, 197.3, 169.6, 168.8, 152.1, 127.4, 124.9, 124.3, 76.6, 65.5, 55.9, 48.5, 45.3, 40.1, 38.7, 35.0, 34.0, 30.7, 30.3, 25.8, 23.3, 21.7, 21.1, 20.8; *m/z* 442.5 [M<sup>+</sup>].

(-)-8-Phenylmenthyl (1*S*,2*S*,4*R*)-1-Acetylamino-2,4-diformylcyclopentanecarboxylate 4b: crude compound; IR  $\nu_{max}$ 3390, 1727, 1651 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>)  $\delta$  9.69 (d, *J* = 1.5 Hz, 1 H), 9.61 (d, *J* = 1.3 Hz, 1 H), 7.32–7.15 (m, 5 H), 6.05 (s, 1 H, exch.), 5.04–4.95 (m, 1 H), 3.27–3.12 (m, 1 H), 2.43 (dd, *J* = 14.0, 10.0 Hz, 1 H), 2.33 (dd, *J* = 9.3, 9.2 Hz, 1 H), 2.12–1.95 (m, 2 H), 1.97 (s, 3 H), 1.90–1.80 (m, 2 H), 1.72–1.55 (m, 3 H), 1.50–1.40 (m, 1 H), 1.36 (s, 3 H), 1.22 (s, 3 H), 1.18–0.80 (m, 3 H), 0.90 (d, *J* = 6.5 Hz, 3 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  202.0, 200.1, 171.5, 170.3, 151.7, 128.7, 125.9, 78.8, 67.1, 57.9, 50.3, 48.9, 41.8, 40.3, 35.6, 34.6, 31.8, 27.7, 27.3, 27.0, 26.5, 24.5, 22.1; *m/z* 442.5 [M<sup>+</sup>].

General Procedure for the Reductive Amination: Synthesis of 3-Azabicyclo[3.2.1]octane Derivatives 5a,b. Aldehyde [3a/4a

(242 mg, 1 mmol); **3b/4b** (442 mg, 1 mmol)] was dissolved in anhydrous dichloroethane (4 mL) under nitrogen. Operating under stirring at room temperature, *p*-methoxybenzylamine (137.2 mg, 1 mmol), NaBH(OAc)<sub>3</sub> (487.0 mg, 2.3 mmol), and a catalytic amount of AcOH were added. After 4 h, the solvent was evaporated, and the crude reaction mixture was taken up with CH<sub>2</sub>Cl<sub>2</sub> (5 mL). The organic layer was washed with H<sub>2</sub>O (5 mL) and dried over MgSO<sub>4</sub>. The crude reaction was chromatographed on silica gel (**5a**, CH<sub>2</sub>Cl<sub>2</sub>/ MeOH = 20:1; **5b**, CH<sub>2</sub>Cl<sub>2</sub>/MeOH = 50:1) giving pure 3-azabicyclo-[3.2.1]octane derivatives **5** after crystallization [**3a**, *exo*-**5a** (211 mg, 61%); **4a**, *endo*-**5a** (183 mg, 53%); **3a/4a**, *exo*-**5a** (141 mg, 41%); *endo*-**5a** (52 mg, 15%); **3b**; *exo*-**5b** (311 mg, 57%); **4b**, *endo*-**5b** (317 mg, 58%)].

Methyl (1*S*\*,5*S*\*,6*S*\*)-6-(Acetylamino)-3-(4-methoxybenzyl)-3-azabicyclo[3.2.1]octane-6-carboxylate *exo*-5a: Mp 143–145 °C (benzene); IR  $\nu_{max}$  3344, 1737, 1637 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.16, 6.84 (AA'XX' system, *J* = 8.4 Hz, 4 H), 6.44 (s, 1 H, exch.), 3.78 (s, 3 H), 3.67 (s, 3 H), 3.55, 3.17 (AB system, *J* = 12.5 Hz, 2 H), 2.83–2.75 (m, 1 H), 2.72 (br s, 1 H), 2.56–2.50 (m, 1 H), 2.40–2.30 (m, 2 H), 2.20 (br s, 1 H), 2.03–1.98 (m, 2 H), 1.72 (dd, *J* = 13.5, 2.5 Hz, 1 H), 1.57 (s, 3 H), 1.50 (dd, *J* = 11.1, 2.5 Hz, 1 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 174.4, 171.0, 159.2, 130.6, 130.6, 114.2, 65.9, 62.2, 61.0, 55.6, 54.9, 52.5, 43.0, 40.0, 37.1, 34.7, 22.5; *m*/z 347.3 [M<sup>+</sup>]. Anal. Calcd for C<sub>19</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub>: C, 65.87; H, 7.56; N, 8.09. Found: C, 65.85; H, 7.55; N, 8.06.

**Methyl** (1*R*\*,5*R*\*,6*S*\*)-6-(Acetylamino)-3-(4-methoxybenzyl)-3-azabicyclo[3.2.1]octane-6-carboxylate *endo*-5a: Mp 155–157 °C (benzene); IR  $\nu_{max}$  3265, 1747, 1640 cm<sup>-1</sup>; <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 7.23, 6.84 (AA'XX' system, *J* = 8.5 Hz, 4 H), 5.72 (s, 1 H, exch.), 3.80 (s, 3 H), 3.69 (s, 3 H), 3.42, 3.33 (AB system, *J* = 13.0 Hz, 2 H), 3.01 (dd, *J* = 13.9, 1.8 Hz, 1 H), 2.84 (d, *J* = 10.2 Hz, 1 H), 2.71 (d, *J* = 8.4 Hz, 1 H), 2.30 (br s, 1 H), 2.30–1.85 (m, 5 H), 1.96 (s, 3 H), 1.51 (dd, *J* = 11.3, 2.2 Hz, 1 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ 172.5, 169.7, 159.0, 131.1, 130.4, 113.9, 68.5, 62.0, 59.0, 55.9, 55.6, 52.5, 46.8, 39.9, 37.1, 35.1, 23.7; *m/z* 347.3 [M<sup>+</sup>]. Anal. Calcd for C<sub>19</sub>H<sub>26</sub>N<sub>2</sub>O<sub>4</sub>: C, 65.87; H, 7.56; N, 8.09. Found: C, 65.91; H, 7.54; N, 8.08.

(-)-Phenylmenthyl (1*S*,*S*,*S*,*S*)-6-(Acetylamino)-3-(4-methoxybenzyl)-3-azabicyclo[3.2.1]octane-6-carboxylate *exo*-5b: Mp 186 °C (*i*-Pr<sub>2</sub>O);  $[\alpha]^{25}_{D} = -46.5^{\circ}$  (*c* 5.24, CHCl<sub>3</sub>); IR  $\nu_{max}$  3400, 1730, 1657 cm<sup>-1</sup>; <sup>1</sup> H NMR (CDCl<sub>3</sub>)  $\delta$  7.28–7.08 (m, 6 H), 7.08–6.98 (m, 1 H), 6.86 (d, J = 8.4 Hz, 2 H), 5.94 (s, 1 H, exch.), 4.81–4.65 (m, 1 H), 3.80 (s, 3 H), 3.54, 3.16 (AB system, J = 12.5 Hz, 2 H), 2.90–2.70 (m, 1 H), 2.65–2.00 (m, 4 H), 2.00–1.80 (m, 2 H), 1.60–0.70 (m, 11 H), 1.58 (s, 3 H), 1.30 (s, 3 H), 1.19 (s, 3 H), 0.83 (d, J = 6.2 Hz, 3 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  173.3, 170.6, 159.2, 151.7, 131.0, 130.5, 128.1, 125.9, 125.2, 114.1, 76.7, 66.2, 62.2, 60.9, 55.6, 54.8, 50.4, 42.1, 41.1, 40.3, 36.7, 34.9, 34.7, 31.5, 28.4, 27.6, 25.0, 23.1, 22.7, 22.0; m/z 547.3 [M<sup>+</sup>]. Anal. Calcd for C<sub>34</sub>H<sub>46</sub>N<sub>2</sub>O<sub>4</sub>: C, 74.69; H, 8.48; N, 5.12. Found: C, 74.53; H, 8.50; N, 5.09.

(-)-Phenylmenthyl (1*R*,5*R*,6*S*)-6-(Acetylamino)-3-(4-methoxybenzyl)-3-azabicyclo[3.2.1]octane-6-carboxylate *endo*-5b: Mp 86 °C (CH<sub>2</sub>Cl<sub>2</sub>/*i*Pr<sub>2</sub>O); [ $\alpha$ ]<sup>25</sup><sub>D</sub> = -3.5° (*c* 6.4, CHCl<sub>3</sub>); IR  $\nu_{max}$  3400, 1730, 1657 cm<sup>-1</sup>; <sup>1</sup> H NMR (CDCl<sub>3</sub>)  $\delta$  7.42–7.05 (m, 6 H), 7.05– 6.95 (m, 1 H), 6.88 (d, *J* = 8.8 Hz, 2 H), 5.42 (s, 1 H, exch.), 4.78–4.66 (m, 1 H), 3.82 (s, 3 H), 3.55, 3.22 (AB system, *J* = 13.0 Hz, 2 H), 2.90–2.80 (m, 1 H), 2.58–162 (m, 10 H), 1.57 (s, 3H), 1.58–0.70 (m, 7 H), 1.29 (s, 3 H), 1.15 (s, 3 H), 0.84 (d, *J* = 6.2 Hz, 3 H); <sup>13</sup>C NMR (CDCl<sub>3</sub>)  $\delta$  171.0, 169.4, 158.8, 152.3, 131.0, 130.2, 128.1, 125.8, 125.2, 113.7, 77.3, 68.5 61.5, 58.1, 55.7, 55.4, 50.2, 41.1, 40.3, 39.1, 37.1, 35.0, 34.6, 31.6, 28.3, 27.6, 25.4, 23.5, 23.1, 22.1; *m*/z 547.3 [M<sup>+</sup>]. Anal. Calcd for C<sub>34</sub>H<sub>46</sub>N<sub>2</sub>O<sub>4</sub>: C, 74.69; H, 8.48; N, 5.12. Found: C, 74.50; H, 8.51; N, 5.07.

General Procedure for the Oxidative Deprotection of 5a. To a solution of compound 5a (346 mg, 1 mmol) in acetone/H<sub>2</sub>O (23 mL, 9:1) at 0 °C was added (NH<sub>4</sub>)<sub>2</sub>Ce(NO<sub>3</sub>)<sub>6</sub> (2.19 g, 4 mmol) in several portions in 1 h. The mixture was stirred at room temperature for 3 h and quenched with a saturated solution of NaHCO<sub>3</sub> (pH 10). A solid was formed. Acetone was evaporated, and the aqueous layer was filtered through a Celite pad. After elution with warm EtOH, the organic solution was concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH = 5:1:0.025). Compound **6** (*exo*-**6a**, 204 mg, 90%; *endo*-**6a**, 141 mg, 62%) was isolated after recrystallization.

**Methyl** (1*S*\*,5*S*\*,6*S*\*)-6-(Acetylamino)-3-azabicyclo[3.2.1]octane-6-carboxylate *exo*-6a: Mp 110 °C dec (EtOH); IR  $\nu_{max}$  3400, 1727, 1632 cm<sup>-1</sup>; <sup>1</sup>H NMR (D<sub>2</sub>O)  $\delta$  3.58 (s, 3 H), 3.10 (br s, 4 H), 2.86 (br s, 1 H), 2.55 (dd, *J* = 15.4, 7.3 Hz, 1 H), 2.39 (br s, 1 H), 2.11–1.98 (m, 1 H), 1.92 (s, 3 H), 1.83 (dd, *J* = 15.4, 3.0 Hz, 1 H), 1.71 (dd, *J* = 12.5, 2.6 Hz, 1 H); <sup>13</sup>C NMR (D<sub>2</sub>O)  $\delta$ 176.5, 175.5, 65.0, 53.5, 49.2, 45.9, 39.2, 38.8, 34.2, 32.0, 21.9; *m*/*z* 227.2 [M<sup>+</sup>]. Anal. Calcd for C<sub>11</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>: C, 58.39; H, 8.02; N, 12.38. Found: C, 58.21; H, 8.18; N, 12.22.

Methyl (1*R*\*,5*R*\*,6*S*\*)-6-(Acetylamino)-3-azabicyclo[3.2.1]octane-6-carboxylate *endo*-6a: Mp 99 °C dec (EtOH); IR  $\nu_{max}$ 3420, 1720, 1645 cm<sup>-1</sup>; <sup>1</sup>H NMR (D<sub>2</sub>O)  $\delta$  3.66 (s, 3 H), 3.21 (d, *J* = 12.5 Hz, 1H), 3.18–3.00 (m, 3 H), 2.56 (d, *J* = 15.7 Hz, 1 H), 2.47 (br s, 2 H), 2.21–2.00 (m, 2 H), 1.93 (s, 3 H), 1.75 (d, *J* = 12.5 Hz, 1 H); <sup>13</sup>C NMR (D<sub>2</sub>O)  $\delta$  175.1, 173.9, 66.9, 53.9, 49.6, 45.8, 42.3, 39.8, 34.4, 32.5, 21.7; *m*/*z* 227.1 [M<sup>+</sup>]. Anal. Calcd for C<sub>11</sub>H<sub>18</sub>N<sub>2</sub>O<sub>3</sub>: C, 58.39; H, 8.02; N, 12.38. Found: C, 58.30; H, 8.20; N, 12.14.

**6-Acetylamino-3-(4-methoxybenzyl)-3-azabicyclo[3.2.1]octane-6-carboxylic Acid** ( $\pm$ )-**7:** Operating in a sealed tube, compound **5a** (346 mg, 1 mmol) was dissolved in EtOH (95%, 5 mL), and KOH (112.2 mg, 2 mmol) was added. The solution was heated at 120 °C under stirring for 2 h. The reaction mixture was treated with HCl (6 N, pH 7), and the solvent was removed. The crude material was filtered through a pad of silica gel with CH<sub>2</sub>Cl<sub>2</sub>/CH<sub>3</sub>-OH (5:2). Crystallization from absolute EtOH afforded the pure carboxylic acid derivative **7** [( $\pm$ )-*exo*-**7** (315 mg, 95%); ( $\pm$ )-*endo*-**7** (330 mg, 99%)].

(1*S*\*,5*S*\*,6*S*\*)-(±)-*exo*-7: Mp 200 °C (EtOH); IR  $\nu_{max}$  3412, 1740, 1661 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD) δ 7.61, 7.00 (AA'XX' system, J = 8.4 Hz, 4 H), 4.42, 4.01 (AB system, J = 11.0 Hz, 2 H), 3.83 (s, 3H), 3.56, 3.17 (AB system, J = 11.0 Hz, 2 H), 3.10–1.90 (br s, 2 H), 2.81 (d, J = 12.2 Hz, 1 H), 2.63 (d, J = 14.2 Hz, 1 H), 2.50 (br s, 1 H), 2.41 (dd, J = 14.7, 7.0 Hz, 1 H), 2.38–2.29 (m, 1 H), 1.92 (s, 3 H), 1.78 (d, J = 11.2 Hz, 1 H); <sup>13</sup>C NMR (CD<sub>3</sub>-OD) δ 176.9, 172.7, 160.2, 131.5, 120.9, 113.4, 65.0, 59.7, 57.6, 53.8, 53.0, 40.0, 36.4, 33.9, 32.8, 20.9; *m*/z 333.2 [M<sup>+</sup>]. Anal. Calcd for C<sub>18</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>: C, 65.04; H, 7.28; N, 8.43. Found: C, 65.12; H, 7.38; N, 8.50.

(1*R*\*,5*R*\*,6*S*\*)-(±)-endo-7: Mp 202 °C dec (EtOH); IR  $\nu_{max}$  3435, 1613, 1516 cm<sup>-1</sup>; <sup>1</sup>H NMR (CD<sub>3</sub>OD)  $\delta$  7.42, 6.98 (AA'XX' system, J = 8.4 Hz, 4 H), 4.16, (br s, 2 H), 3.80 (s, 3 H), 3.40–3.20 (m, 3 H), 3.11 (d, J = 12.1 Hz, 1 H), 2.66 (d, J = 15.0 Hz, 1 H), 2.53 (br s, 2 H), 2.30–2.02 (m, 2 H), 1.92 (s, 3 H), 1.88 (d, J = 11.5 Hz, 1 H); <sup>13</sup>C NMR (CD<sub>3</sub>OD)  $\delta$  177.2, 170.9, 160.2, 131.1, 120.7, 113.6, 67.6, 58.7, 56.2, 54.4, 53.8, 42.3, 41.2, 33.8, 33.6, 20.8; m/z 333.3 [M<sup>+</sup>]. Anal. Calcd for C<sub>18</sub>H<sub>24</sub>N<sub>2</sub>O<sub>4</sub>: C, 65.04; H, 7.28; N, 8.43. Found: C, 65.00; H, 7.30; N, 8.39.

General Procedure for the Hydrolysis of Amino Acid Function. (i) Operating in a sealed tube, compounds  $(\pm)$ -*exo*-**5a**,**6a** or  $(\pm)$ -*endo*-**5a**,**6a** (1 mmol) were suspended in HCl (1 mL, 6 M), and the mixture was heated at 120 °C for 24 h. The solvent was removed, and the crude amino acids  $(\pm)$ -*exo*-**8** (mixture of conformers 7:1), *exo*-**9**, and  $(\pm)$ -*endo*-**8**,**9** were isolated as bischlorohydrate in quantitative yield. (ii) Operating in a sealed tube, MeOH (5 mL) was cooled at 0 °C, and Na (161 mg, 7 mmol) was added. Compound **5b** (546.7 mg, 1 mmol) was added, and the mixture was heated at 100 °C under stirring for 50 h (TLC, CH<sub>2</sub>-Cl<sub>2</sub>/MeOH, 50:1). The solvent was removed, and the crude reaction mixture was taken up with distilled H<sub>2</sub>O (5 mL) and extracted with AcOEt (3 × 10 mL). The aqueous solution was treated with HCl (6 N, pH 1) and was purified by a Dowex 50W × 4–50 ion-exchange resin which was first activated with NH<sub>4</sub>OH (2 N) then with AcOH (2 N, pH 4) followed by washing with H<sub>2</sub>O (pH 7). The reaction mixture was deposited on the resin which was rinsed with water. The amino acid was eluted with aqueous NH<sub>4</sub>OH (2 N). Ninhydrin positive fractions (TLC, CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH-(15%) = 5:3:0.9) were pooled and evaporated to give (-)-*exo*-**8** (130 mg, 45%) from (-)-*exo*-**5b** and (-)-*endo*-**8** (172 mg, 60%) from (-)-*endo*-**5b**.

**6-Amino-3-(4-methoxybenzyl)-3-azabicyclo[3.2.1]octane-6carboxylic Acids:** (**1***S*\*,**5***S*\*,**6***S*\*) (±)-*exo*-**8**·2 **HCI:** mixture of isomers (8:1); mp 176 °C (acetone/H<sub>2</sub>O); IR  $\nu_{max}$  3470–3370, 1742, 1614 cm<sup>-1</sup>; <sup>1</sup>H NMR (D<sub>2</sub>O)  $\delta$  (major isomer) 7.32, 6.92 (AA'BB' system, *J* = 8.8 Hz, 4 H), 4.29, 4.13 (AB system, *J* = 12.8 Hz, 2 H), 3.70 (s, 3 H), 3.52, 3.37 (AB system, *J* = 14.3 Hz, 2 H), 3.15 (br s, 2 H), 2.70–2.55 (m, 2 H), 2.52–2.48 (m, 1 H), 2.30–2.10 (m, 1 H), 1.62 (d, *J* = 4.0 Hz, 1 H), 1.56 (d, *J* = 8.4 Hz, 1 H); (minor isomer (significative signals)) 7.18, 6.80 (AA'BB' system, *J* = 8.8 Hz, 4 H); <sup>13</sup>C NMR (D<sub>2</sub>O)  $\delta$  173.1, 160.5, 133.3 (133.5), 120.3, 114.5 (115.9), 64.6, 61.9, 57.5, 55.5, 52.5, 41.5, 33.8, 33.0, 32.5; *m*/z 291.8 [M<sup>+</sup>]. Anal. Calcd for C<sub>16</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub>: C, 52.90; H, 6.66; N, 7.71. Found: C, 52.50; H, 7.00; N, 7.28.

(1S,5S,6S) (-)-*exo*-8:  $[\alpha]^{25}_{D} = -36.3^{\circ}$  (*c* 3.7, MeOH).

(1*R*\*,5*R*\*,6*S*\*) (±)-*endo*-8·2 HCl: mixture of isomers (3:1); mp 220-221 °C (EtOH); IR  $\nu_{max}$  3405-2950, 1725, 1614 cm<sup>-1</sup>; <sup>1</sup>H NMR (D<sub>2</sub>O)  $\delta$  (major isomer) 7.35, 7.01 (AA'BB' system, *J* = 8.8 Hz, 4 H), 4.18, 4.12 (AB system, *J* = 13.1 Hz, 2 H), 3.79 (s, 3 H), 3.44, 3.16 (AB system, *J* = 11.2 Hz, 2 H), 3.28-3.13 (m, 2 H), 2.71 (br s, 1 H), 2.66 (br s, 1 H), 2.46 (dd, *J* = 15.7, 2.1 Hz, 1 H), 2.17 (dd system, *J* = 15.7, 7.2 Hz, 1 H), 2.09-2.07 (m, 1 H), 1.94 (d, *J* = 13.5 Hz, 1 H); (minor isomer (significative signals)) 7.28, 6.90 (AA'BB' system, *J* = 8.8 Hz, 4 H); <sup>13</sup>C NMR (D<sub>2</sub>O)  $\delta$  174.6, 160.3, 132.4 (132.2), 121.3 (120.6), 114.9 (116.2), 67.1, 59.96 (60.03), 56.99 (56.93), 55.5, 54.5, 42.8, 38.9, 34.2, 33.9; *m*/*z* 291.8 [M<sup>+</sup>]. Anal. Calcd for C<sub>16</sub>H<sub>24</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub>: C, 52.90; H, 6.66; N, 7.71. Found: C, 52.53; H, 7.69; N, 7.29.

(1R,5R,6S) (-)-*endo*-8:  $[\alpha]^{25}_{D} = -14.0^{\circ}$  (*c* 4.25, MeOH).

(1*S*\*,5*S*\*,6*S*\*)-6-Amino-3-azabicyclo[3.2.1]octane-6-carboxylic Acid 2 HCl ( $\pm$ )-*exo*-9: IR  $\nu_{max}$  3600–2950, 1695, 1626 cm<sup>-1</sup>; <sup>1</sup>H NMR (2·HCl salt D<sub>2</sub>O)  $\delta$  3.51 (dd, J = 14.6, 3.1 Hz, 1 H), 3.45 (dt, J = 14.6, 2.2 Hz, 1 H), 3.37–3.24 (m, 2 H), 2.89 (dd, J = 15.9, 8.0 Hz, 1 H), 2.78 (br s, 1 H), 2.62 (br s, 1 H), 2.45–2.28 (m, 1 H), 1.85 (dd, J = 15.9, 1.9 Hz, 1 H), 1.79 (dd, J = 13.0, 2.1 Hz, 1 H); <sup>13</sup>C NMR  $\delta$  172.6, 63.1, 48.9, 42.9, 39.6, 33.6, 32.2, 31.0; m/z 172.2 [M]<sup>+</sup>. Anal. Calcd for C<sub>8</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>: C, 39.52; H, 6.63; N, 11.52. Found: C, 39.05; H, 6.96; N, 11.30.

(1*R*\*,5*R*\*,6*S*\*)-6-Amino-3-azabicyclo[3.2.1]octane-6-carboxylic Acid 2 HCl ( $\pm$ )-*endo*-9: IR  $\nu_{max}$  3600–2950, 1697, 1627 cm<sup>-1</sup>; <sup>1</sup>H NMR (D<sub>2</sub>O)  $\delta$  3.35 (dt, *J* = 12.7, 2.4 Hz, 1 H), 3.27 (br s, 2 H), 3.23 (d, *J* = 12.7 Hz, 1 H), 2.71 (br s, 1 H), 2.68 (br s, 1 H), 2.57 (dd, *J* = 15.9, 2.1 Hz, 1 H), 2.24 (dd, *J* = 15.9, 7.4 Hz, 1 H), 2.20–2.12 (m, 1 H), 1.98 (dd, *J* = 13.2, 2.1 Hz, 1 H); <sup>13</sup>C NMR (D<sub>2</sub>O)  $\delta$  173.2, 66.3, 48.4, 45.7, 41.4, 37.7, 33.2, 32.6; *m*/*z* 172.2 [M]<sup>+</sup>. Anal. Calcd for C<sub>8</sub>H<sub>16</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>: C, 39.52; H, 6.63; N, 11.52. Found: C, 39.01; H, 6.98; N, 11.28.

(1*S*\*,5*S*\*,6*S*\*) Methyl 6-Amino-3-azabicyclo[3.2.1]octane-6carboxylate (±)-*exo*-10: Amino acid *exo*-9 (53 mg, 0.31 mmol) was dissolved in MeOH (3 mL), and SOCl<sub>2</sub> was added (100  $\mu$ L, 0.62 mmol), and the mixture was refluxed for 5 h. After cooling, the reaction mixture was treated with a saturated solution of NaHCO<sub>3</sub> (pH 10). The solid was filtered, and the solution, after solvent evaporation of the solvent, was chromatographed on silica gel (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH(15%) = 25:5:0.1). Compound (±)-*exo*-10 was isolated and crystallized (51 mg, 89%): Mp 250 °C dec (EtOH); IR  $\nu_{max}$  3466, 1731, 1637 cm<sup>-1</sup>; <sup>1</sup>H NMR (D<sub>2</sub>O)  $\delta$ 3.77 (s, 3 H), 3.30–3.05 (m, 4 H), 2.57 (br s, 1 H), 2.40–1.95 (m, 4 H), 1.75 (dd, *J* = 12.4, 1.8 Hz, 1 H); <sup>13</sup>C NMR  $\delta$  175.8, 81.3, 53.0, 49.0, 44.8, 44.3, 40.9, 33.4, 31.8. Anal. Calcd for C<sub>9</sub>H<sub>16</sub>N<sub>2</sub>O<sub>2</sub>: C, 58.67; H, 8.75; N, 15.21. Found: C, 56.60; H, 8.78; N, 15.18.

Acknowledgment. We thank MIUR (PRIN 2004) for financial support.

**Supporting Information Available:** General technique, NMR discussion for compounds **5a**, and <sup>1</sup>H and <sup>13</sup>C NMR spectra of **2–10**. This material is available free of charge via the Internet at http://pubs.acs.org.

JO061391O